• Home Study Details

  • Home / Learn / Home Study CE / Home Study Details


Genomic Testing - Individualizing Breast Cancer Treatment

Program Type

OnDemand

Credits

1 Contact Hour(s)

Release Date

Sunday, May 5, 2019

Offline Date:

Tuesday, May 5, 2020

ACPE Expiration Date

Friday, November 5, 2021

Target Audience

Nurse, Pharmacist

Cost

$0.00

  • Overview

    Breast cancer occurs in about 10 - 15% of women in the United States. While the overall breast cancer death rate has dropped significantly, early detection and treatment certainly offers greater chances for survival. Advances in medical technology offer more effective treatment options. Genomic testing assists in individualizing treatment and helps determine whether chemotherapy is appropriate therapy to prevent recurrence. While pharmacists and pharmacies certainly have a role in screening and early detection, pharmacists should also understand the role of genomic testing in individualizing treatment of early stage breast cancer after surgery to remove tumors. 



    Handouts

    Slide Document:   18203H01_6pp.pdf
    Slide Document:   18203H01_2pp.pdf

    Financial Support By

    Merck & Co.
  • Nurse

    Describe the use and incorporation of the Breast Recurrence Score test as the recognized standard of care in breast cancer treatment guidelines to individualize treatment decisions after tumor removal
    Outline the recent study findings on genomics testing of tumors and considerations for adjuvant therapy
    Identify strategies to explain to patients the clinical value of genomic testing in individualizing adjuvant therapy in early stage breast cancer after tumor removal


    Pharmacist

    Describe the use and incorporation of the Breast Recurrence Score test as the recognized standard of care in breast cancer treatment guidelines to individualize treatment decisions after tumor removal
    Outline the recent study findings on genomics testing of tumors and considerations for adjuvant therapy
    Identify strategies to explain to patients the clinical value of genomic testing in individualizing adjuvant therapy in early stage breast cancer after tumor removal

  • Activity Type

    Knowledge

    Universal Activity Number

    Nurse 0798-0000-18-203-H01-N

    Pharmacist 0798-0000-18-203-H01-P

    ACPE PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

    In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


HARDWARE REQUIREMENTS
Standard Windows/Mac System
iPad or iPhone
Minimum screen resolution: 1024x768
Speakers or headphones
 


SOFTWARE REQUIREMENTS
Microsoft Edge
Internet Explorer 8.0 or higher
Google Chrome
Safari
Firefox 3.0.3 or higher


NETWORK REQUIREMENTS
Broadband Internet Connection:
T1, Hi-speed DSL or Cable
4G cellular connection
 
 

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

 

©2015 PharmCon, lnc. All Rights Reserved | Terms & Conditions | Privacy PolicyContinuing Education For Healthcare Professionals
Developed By: ITB, Inc.